Which has stronger valuation and earnings, SIBN or TMDX?

TransMedics Group has higher revenue and earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SiBone $200.93M 4.34 -$18.90M -$0.34 N/A TransMedics Group $605.49M 4.04 $190.29M $3.89 18.20

Does the media favor SIBN or TMDX?

In the previous week, SiBone had 2 more articles in the media than TransMedics Group. MarketBeat recorded 8 mentions for SiBone and 6 mentions for TransMedics Group. SiBone's average media sentiment score of 0.92 beat TransMedics Group's score of 0.01 indicating that SiBone is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SiBone 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TransMedics Group 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, ATRC or SIBN?

AtriCure has higher revenue and earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AtriCure $534.53M 5.34 -$11.45M $0.21 267.00 SiBone $200.93M 4.34 -$18.90M -$0.34 N/A

Is ATRC or SIBN more profitable?

AtriCure has a net margin of 1.85% compared to SiBone's net margin of -6.85%. AtriCure's return on equity of 2.34% beat SiBone's return on equity. Company Net Margins Return on Equity Return on Assets AtriCure 1.85% 2.34% 1.77% SiBone -6.85% -8.23% -6.07%

Does the media refer more to ATRC or SIBN?

In the previous week, SiBone had 4 more articles in the media than AtriCure. MarketBeat recorded 8 mentions for SiBone and 4 mentions for AtriCure. AtriCure's average media sentiment score of 0.92 beat SiBone's score of 0.92 indicating that AtriCure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AtriCure 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SiBone 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, BFLY or SIBN?

SiBone has higher revenue and earnings than Butterfly Network. SiBone is trading at a lower price-to-earnings ratio than Butterfly Network, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Butterfly Network $97.61M 19.77 -$77.06M -$0.29 N/A SiBone $200.93M 4.34 -$18.90M -$0.34 N/A

Does the media refer more to BFLY or SIBN?

In the previous week, SiBone had 1 more articles in the media than Butterfly Network. MarketBeat recorded 8 mentions for SiBone and 7 mentions for Butterfly Network. SiBone's average media sentiment score of 0.92 beat Butterfly Network's score of 0.44 indicating that SiBone is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Butterfly Network 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SiBone 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to INSP or SIBN?

In the previous week, SiBone had 4 more articles in the media than Inspire Medical Systems. MarketBeat recorded 8 mentions for SiBone and 4 mentions for Inspire Medical Systems. Inspire Medical Systems' average media sentiment score of 1.46 beat SiBone's score of 0.92 indicating that Inspire Medical Systems is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inspire Medical Systems 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SiBone 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SIBN or ESTA more profitable?

SiBone has a net margin of -6.85% compared to Establishment Labs' net margin of -15.82%. SiBone's return on equity of -8.23% beat Establishment Labs' return on equity. Company Net Margins Return on Equity Return on Assets SiBone -6.85% -8.23% -6.07% Establishment Labs -15.82% -196.69% -10.73%

Does the media favor SIBN or ESTA?

In the previous week, SiBone and SiBone both had 8 articles in the media. SiBone's average media sentiment score of 0.92 beat Establishment Labs' score of 0.32 indicating that SiBone is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SiBone 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Establishment Labs 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

SiBone (SIBN) Competitors

$19.68 -0.23 (-1.16%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$19.76 +0.08 (+0.41%)

As of 10/16/2026 07:30 PM Eastern

Compare

SIBN vs. TMDX, ATRC, BFLY, INSP, and ESTA

Should you buy SiBone stock or one of its competitors? SiBone's main competitors and comparable companies include TransMedics Group (TMDX), AtriCure (ATRC), Butterfly Network (BFLY), Inspire Medical Systems (INSP), and Establishment Labs (ESTA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does SiBone compare to TransMedics Group?

SiBone (NASDAQ:SIBN) and TransMedics Group (NASDAQ:TMDX) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, risk and profitability.

SiBone currently has a consensus target price of $24.50, suggesting a potential upside of 24.49%. TransMedics Group has a consensus target price of $115.60, suggesting a potential upside of 63.32%. Given TransMedics Group's higher probable upside, analysts plainly believe TransMedics Group is more favorable than SiBone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
TransMedics Group	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, SiBone had 2 more articles in the media than TransMedics Group. MarketBeat recorded 8 mentions for SiBone and 6 mentions for TransMedics Group. SiBone's average media sentiment score of 0.92 beat TransMedics Group's score of 0.01 indicating that SiBone is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SiBone	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TransMedics Group	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

SiBone has a beta of 0.66, meaning that its share price is 34% less volatile than the broader market. Comparatively, TransMedics Group has a beta of 1.94, meaning that its share price is 94% more volatile than the broader market.

98.1% of SiBone shares are held by institutional investors. Comparatively, 99.7% of TransMedics Group shares are held by institutional investors. 4.0% of SiBone shares are held by company insiders. Comparatively, 6.9% of TransMedics Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

TransMedics Group has higher revenue and earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SiBone	$200.93M	4.34	-$18.90M	-$0.34	N/A
TransMedics Group	$605.49M	4.04	$190.29M	$3.89	18.20

TransMedics Group has a net margin of 22.69% compared to SiBone's net margin of -6.85%. TransMedics Group's return on equity of 15.88% beat SiBone's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SiBone	-6.85%	-8.23%	-6.07%
TransMedics Group	22.69%	15.88%	5.95%

Summary

TransMedics Group beats SiBone on 11 of the 16 factors compared between the two stocks.

How does SiBone compare to AtriCure?

AtriCure (NASDAQ:ATRC) and SiBone (NASDAQ:SIBN) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, media sentiment, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.

99.1% of AtriCure shares are held by institutional investors. Comparatively, 98.1% of SiBone shares are held by institutional investors. 4.0% of AtriCure shares are held by company insiders. Comparatively, 4.0% of SiBone shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

AtriCure currently has a consensus price target of $54.10, indicating a potential downside of 3.51%. SiBone has a consensus price target of $24.50, indicating a potential upside of 24.49%. Given SiBone's stronger consensus rating and higher possible upside, analysts plainly believe SiBone is more favorable than AtriCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AtriCure	0 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.58
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

AtriCure has a net margin of 1.85% compared to SiBone's net margin of -6.85%. AtriCure's return on equity of 2.34% beat SiBone's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AtriCure	1.85%	2.34%	1.77%
SiBone	-6.85%	-8.23%	-6.07%

AtriCure has higher revenue and earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AtriCure	$534.53M	5.34	-$11.45M	$0.21	267.00
SiBone	$200.93M	4.34	-$18.90M	-$0.34	N/A

In the previous week, SiBone had 4 more articles in the media than AtriCure. MarketBeat recorded 8 mentions for SiBone and 4 mentions for AtriCure. AtriCure's average media sentiment score of 0.92 beat SiBone's score of 0.92 indicating that AtriCure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AtriCure	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SiBone	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AtriCure has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market. Comparatively, SiBone has a beta of 0.66, meaning that its share price is 34% less volatile than the broader market.

Summary

AtriCure beats SiBone on 12 of the 15 factors compared between the two stocks.

How does SiBone compare to Butterfly Network?

Butterfly Network (NYSE:BFLY) and SiBone (NASDAQ:SIBN) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends and analyst recommendations.

In the previous week, SiBone had 1 more articles in the media than Butterfly Network. MarketBeat recorded 8 mentions for SiBone and 7 mentions for Butterfly Network. SiBone's average media sentiment score of 0.92 beat Butterfly Network's score of 0.44 indicating that SiBone is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Butterfly Network	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
SiBone	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

37.9% of Butterfly Network shares are owned by institutional investors. Comparatively, 98.1% of SiBone shares are owned by institutional investors. 22.0% of Butterfly Network shares are owned by insiders. Comparatively, 4.0% of SiBone shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Butterfly Network currently has a consensus target price of $8.75, suggesting a potential upside of 20.77%. SiBone has a consensus target price of $24.50, suggesting a potential upside of 24.49%. Given SiBone's higher possible upside, analysts clearly believe SiBone is more favorable than Butterfly Network.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Butterfly Network	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

SiBone has higher revenue and earnings than Butterfly Network. SiBone is trading at a lower price-to-earnings ratio than Butterfly Network, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Butterfly Network	$97.61M	19.77	-$77.06M	-$0.29	N/A
SiBone	$200.93M	4.34	-$18.90M	-$0.34	N/A

Butterfly Network has a beta of 2.04, indicating that its share price is 104% more volatile than the broader market. Comparatively, SiBone has a beta of 0.66, indicating that its share price is 34% less volatile than the broader market.

SiBone has a net margin of -6.85% compared to Butterfly Network's net margin of -66.74%. SiBone's return on equity of -8.23% beat Butterfly Network's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Butterfly Network	-66.74%	-33.99%	-22.96%
SiBone	-6.85%	-8.23%	-6.07%

Summary

SiBone beats Butterfly Network on 10 of the 17 factors compared between the two stocks.

How does SiBone compare to Inspire Medical Systems?

Inspire Medical Systems (NYSE:INSP) and SiBone (NASDAQ:SIBN) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations, media sentiment and institutional ownership.

Inspire Medical Systems has a net margin of 15.03% compared to SiBone's net margin of -6.85%. Inspire Medical Systems' return on equity of 8.64% beat SiBone's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inspire Medical Systems	15.03%	8.64%	7.45%
SiBone	-6.85%	-8.23%	-6.07%

Inspire Medical Systems has higher revenue and earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than Inspire Medical Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inspire Medical Systems	$911.98M	2.18	$145.42M	$4.62	14.87
SiBone	$200.93M	4.34	-$18.90M	-$0.34	N/A

94.9% of Inspire Medical Systems shares are held by institutional investors. Comparatively, 98.1% of SiBone shares are held by institutional investors. 2.2% of Inspire Medical Systems shares are held by insiders. Comparatively, 4.0% of SiBone shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, SiBone had 4 more articles in the media than Inspire Medical Systems. MarketBeat recorded 8 mentions for SiBone and 4 mentions for Inspire Medical Systems. Inspire Medical Systems' average media sentiment score of 1.46 beat SiBone's score of 0.92 indicating that Inspire Medical Systems is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inspire Medical Systems	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SiBone	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Inspire Medical Systems presently has a consensus target price of $68.82, indicating a potential upside of 0.15%. SiBone has a consensus target price of $24.50, indicating a potential upside of 24.49%. Given SiBone's stronger consensus rating and higher possible upside, analysts clearly believe SiBone is more favorable than Inspire Medical Systems.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inspire Medical Systems	4 Sell rating(s)	12 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.05
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Inspire Medical Systems has a beta of 0.73, indicating that its stock price is 27% less volatile than the broader market. Comparatively, SiBone has a beta of 0.66, indicating that its stock price is 34% less volatile than the broader market.

Summary

Inspire Medical Systems beats SiBone on 10 of the 17 factors compared between the two stocks.

How does SiBone compare to Establishment Labs?

SiBone (NASDAQ:SIBN) and Establishment Labs (NASDAQ:ESTA) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

SiBone has a beta of 0.66, indicating that its stock price is 34% less volatile than the broader market. Comparatively, Establishment Labs has a beta of 1.06, indicating that its stock price is 6% more volatile than the broader market.

SiBone has higher earnings, but lower revenue than Establishment Labs. SiBone is trading at a lower price-to-earnings ratio than Establishment Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SiBone	$200.93M	4.34	-$18.90M	-$0.34	N/A
Establishment Labs	$211.08M	8.35	-$51.06M	-$1.31	N/A

SiBone has a net margin of -6.85% compared to Establishment Labs' net margin of -15.82%. SiBone's return on equity of -8.23% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SiBone	-6.85%	-8.23%	-6.07%
Establishment Labs	-15.82%	-196.69%	-10.73%

SiBone currently has a consensus target price of $24.50, suggesting a potential upside of 24.49%. Establishment Labs has a consensus target price of $98.56, suggesting a potential upside of 66.54%. Given Establishment Labs' stronger consensus rating and higher probable upside, analysts plainly believe Establishment Labs is more favorable than SiBone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Establishment Labs	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

In the previous week, SiBone and SiBone both had 8 articles in the media. SiBone's average media sentiment score of 0.92 beat Establishment Labs' score of 0.32 indicating that SiBone is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SiBone	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Establishment Labs	0 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

98.1% of SiBone shares are owned by institutional investors. Comparatively, 72.9% of Establishment Labs shares are owned by institutional investors. 4.0% of SiBone shares are owned by company insiders. Comparatively, 10.0% of Establishment Labs shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

SiBone and Establishment Labs tied by winning 7 of the 14 factors compared between the two stocks.

Get SiBone News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SIBN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SIBN vs. The Competition

Export

Metric	SiBone	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$882.99M	$5.72B	$7.44B	$12.94B
Dividend Yield	N/A	1.73%	2.50%	27.63%
P/E Ratio	-57.88	19.50	198.80	19.05
Price / Sales	4.34	63.47	569.18	76.54
Price / Cash	N/A	32.03	76.54	51.88
Price / Book	4.81	5.73	10.29	5.85
Net Income	-$18.90M	$146.25M	$3.50B	$380.67M
7 Day Performance	1.60%	-2.83%	-5.38%	-5.00%
1 Month Performance	9.09%	-5.29%	-9.56%	-7.94%
1 Year Performance	33.51%	2.88%	0.84%	-5.63%

SiBone Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SIBN SiBone	3.6469 of 5 stars	$19.68 -1.2%	$24.50 +24.5%	+30.3%	$882.99M	$200.93M	N/A	376	Analyst Forecast Insider Trade
TMDX TransMedics Group	4.2276 of 5 stars	$80.19 -3.4%	$121.10 +51.0%	-38.8%	$2.77B	$668.47M	20.61	898	Analyst Forecast
ATRC AtriCure	2.4242 of 5 stars	$53.61 -4.9%	$53.30 -0.6%	+50.6%	$2.73B	$534.53M	255.56	1,350
BFLY Butterfly Network	3.6073 of 5 stars	$8.64 -7.9%	$8.54 -1.1%	+224.9%	$2.29B	$112.14M	N/A	220	Gap Down
INSP Inspire Medical Systems	2.7269 of 5 stars	$68.33 -3.4%	$67.44 -1.3%	-11.2%	$1.97B	$898.74M	14.78	1,333	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SIBN) was last updated on 10/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SiBone (SIBN) Competitors

SIBN vs. TMDX, ATRC, BFLY, INSP, and ESTA

How does SiBone compare to TransMedics Group?

Summary

How does SiBone compare to AtriCure?

Summary

How does SiBone compare to Butterfly Network?

Summary

How does SiBone compare to Inspire Medical Systems?

Summary

How does SiBone compare to Establishment Labs?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SIBN vs. The Competition

SiBone Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

SiBone (SIBN) Competitors

SIBN vs. TMDX, ATRC, BFLY, INSP, and ESTA

How does SiBone compare to TransMedics Group?

Do analysts recommend SIBN or TMDX?

Does the media favor SIBN or TMDX?

Which has more volatility & risk, SIBN or TMDX?

Do institutionals and insiders have more ownership in SIBN or TMDX?

Which has stronger valuation and earnings, SIBN or TMDX?

Is SIBN or TMDX more profitable?

Summary

How does SiBone compare to AtriCure?

Do institutionals and insiders believe in ATRC or SIBN?

Do analysts rate ATRC or SIBN?

Is ATRC or SIBN more profitable?

Which has stronger valuation and earnings, ATRC or SIBN?

Does the media refer more to ATRC or SIBN?

Which has more volatility and risk, ATRC or SIBN?

Summary

How does SiBone compare to Butterfly Network?

Does the media refer more to BFLY or SIBN?

Do institutionals & insiders have more ownership in BFLY or SIBN?

Do analysts recommend BFLY or SIBN?

Which has better earnings & valuation, BFLY or SIBN?

Which has more volatility and risk, BFLY or SIBN?

Is BFLY or SIBN more profitable?

Summary

How does SiBone compare to Inspire Medical Systems?

Is INSP or SIBN more profitable?

Which has higher earnings & valuation, INSP or SIBN?

Do institutionals and insiders believe in INSP or SIBN?

Does the media refer more to INSP or SIBN?

Do analysts prefer INSP or SIBN?

Which has more volatility & risk, INSP or SIBN?

Summary

How does SiBone compare to Establishment Labs?

Which has more risk and volatility, SIBN or ESTA?

Which has higher earnings & valuation, SIBN or ESTA?

Is SIBN or ESTA more profitable?

Do analysts recommend SIBN or ESTA?

Does the media favor SIBN or ESTA?

Do insiders & institutionals believe in SIBN or ESTA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SIBN vs. The Competition

SiBone Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools